ELITE PHARMACEUTICALS INC /NV/ Quarterly Income Tax Expense (Benefit) in USD from Q2 2010 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2010 to Q4 2024.
  • Elite Pharmaceuticals Inc /Nv/ Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $239K.
  • Elite Pharmaceuticals Inc /Nv/ annual Income Tax Expense (Benefit) for 2023 was -$19.6M.
  • Elite Pharmaceuticals Inc /Nv/ annual Income Tax Expense (Benefit) for 2022 was $424K.
  • Elite Pharmaceuticals Inc /Nv/ annual Income Tax Expense (Benefit) for 2021 was -$1.74M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $239K +$1.04M Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-13
Q3 2024 $1.52M* +$19.2M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $232K +$77K +49.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q4 2023 -$17.9M -$801K -$840K -2140% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-13
Q3 2023 -$17.1M -$17.7M* -$17.7M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $579K $155K +$155K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $424K $373K Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $39.3K Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $11.6K +$7.59K +190% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $0 Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-15
Q3 2021 $4K +$1.5K +60% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q3 2020 $2.5K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$946K Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-14
Q2 2018 -$1.05M $0 -$3K -100% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-09
Q1 2018 -$1.05M $3K +$3K Jan 1, 2018 Mar 31, 2018 10-K 2018-06-14
Q4 2017 -$1.05M -$1.05M -$2.92M Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-11
Q3 2017 $1.87M $0 $0 Jul 1, 2017 Sep 30, 2017 10-K 2018-06-14
Q2 2017 $1.87M $3K +$6K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $1.87M $0 +$520K Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 $1.35M $1.87M* +$1.87M Oct 1, 2016 Dec 31, 2016 10-K 2018-06-14
Q3 2016 -$523K $0 $0 Jul 1, 2016 Sep 30, 2016 10-K 2018-06-14
Q2 2016 -$523K -$3K -$3K Apr 1, 2016 Jun 30, 2016 10-K 2018-06-14
Q1 2016 -$520K -$520K -$517K -17233% Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 -$3K $0 $0 Oct 1, 2015 Dec 31, 2015 10-K 2018-06-14
Q3 2015 -$3K $0 $0 Jul 1, 2015 Sep 30, 2015 10-K 2018-06-14
Q2 2015 -$3K $0 $0 Apr 1, 2015 Jun 30, 2015 10-K 2018-06-14
Q1 2015 -$3K -$3K +$292K +99% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 -$295K $0 $0 Oct 1, 2014 Dec 31, 2014 10-K 2017-06-14
Q3 2014 -$295K $0 -$2K -100% Jul 1, 2014 Sep 30, 2014 10-K 2017-06-14
Q2 2014 -$293K $0 $0 Apr 1, 2014 Jun 30, 2014 10-K 2017-06-14
Q1 2014 -$293K -$295K Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 $0 $0 Oct 1, 2013 Dec 31, 2013 10-K 2016-06-15
Q3 2013 $2K +$977 +95.5% Jul 1, 2013 Sep 30, 2013 10-K 2016-06-15
Q2 2013 $0 -$3K -100% Apr 1, 2013 Jun 30, 2013 10-K 2016-06-15
Q4 2012 $0 $0 Oct 1, 2012 Dec 31, 2012 10-Q 2013-02-14
Q3 2012 $1.02K +$1.02K Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $3K +$500 +20% Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-14
Q4 2011 $0 -$1.06K -100% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 $0 -$1.04K -100% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 $2.5K +$2.5K Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q4 2010 $1.06K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 $1.04K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 $0 Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.